On 26 September 2018, the United Nations’ General Assembly will convene the first high-level meeting on tuberculosis; the theme of the meeting is “United to end tuberculosis: an urgent global response to a global epidemic”. In preparation for the United… Continue Reading
The World Health Organization (WHO) and the Government of Denmark have convened a Global Dialogue on Partnerships for Sustainable Financing of Noncommunicable Disease (NCD) Prevention and Control from 9 April 2018 to 11 April 2018 in Copenhagen. The conference is… Continue Reading
On September 10, 2015, the National Association of Manufacturers (NAM), wrote to USTR expressing alarm at the European Union support of an indefinite extension of a WTO waiver of obligations to grant patents on pharmaceuticals for UN defined least developed countries (LDCs). In 2015, there were 954 million persons living in LDCs, with a per capita income of $964, according to the World Bank. The EU had aligned itself with health advocates trying to protect the bottom billion access to life saving medicines.
Update: english translation of letter now available at end this blog.
In a sternly worded letter dated 18 February 2016, the Biotechnology Innovation Organization (BIO), the National Association of Manufacturers (NAM), the National Foreign Trade Council (NFTC), the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. Chamber of Commerce (the Chamber) and the United States Council for International Business (USCIB) wrote Senator Orrin Hatch (Republican – Utah) expressing serious reservations with the United Nations High-Level Panel on Access to Medicines (UN HLP). Continue Reading
|Thaddeus Burns of GE spent months trying to derail the WIPO treaty for the blind negotiations|